Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Giuseppe Ciaramella net worth and biography

Giuseppe Ciaramella Biography and Net Worth

Insider of Beam Therapeutics

Giuseppe Ciaramella, Ph.D. has served as our Chief Scientific Officer since February 2018 and as our President and Chief Scientific Officer since January 2020. Dr. Ciaramella has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics, a biopharmaceutical company, from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, which technology formed the backbone of its authorized vaccine for the prevention of COVID-19. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, a biopharmaceutical company, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, a pharmaceutical company, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer, a biopharmaceutical company, in the U.K. where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London. Provided by Tagnifi.

What is Giuseppe Ciaramella's net worth?: The estimated net worth of Giuseppe Ciaramella is at least $3.17 million as of November 6th, 2024. Dr. Ciaramella owns 109,150 shares of Beam Therapeutics stock worth more than $3,166,442 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Ciaramella may own. Additionally, Dr. Ciaramella receives a salary of $955,550.00 as Insider at Beam Therapeutics. Learn More about Giuseppe Ciaramella's net worth.
How old is Giuseppe Ciaramella?: Dr. Ciaramella is currently 55 years old. There are 4 older executives and no younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics is Dr. Amy Simon M.D., Chief Medical Officer, who is 60 years old. Learn More on Giuseppe Ciaramella's age.
What is Giuseppe Ciaramella's salary?: As the Insider of Beam Therapeutics Inc., Dr. Ciaramella earns $955,550.00 per year. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Giuseppe Ciaramella's salary.
How do I contact Giuseppe Ciaramella?: The corporate mailing address for Dr. Ciaramella and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on Giuseppe Ciaramella's contact information.
Has Giuseppe Ciaramella been buying or selling shares of Beam Therapeutics?: During the last quarter, Giuseppe Ciaramella has sold $2,689,919.30 in shares of Beam Therapeutics stock. Most recently, Giuseppe Ciaramella sold 51,110 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $26.36, for a transaction totalling $1,347,259.60. Following the completion of the sale, the president now directly owns 109,150 shares of the company's stock, valued at $2,877,194. Learn More on Giuseppe Ciaramella's trading history.
Who are Beam Therapeutics' active insiders?: Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.
Are insiders buying or selling shares of Beam Therapeutics?: In the last twelve months, insiders at the sold shares 15 times. They sold a total of 382,107 shares worth more than $10,445,723.95. The most recent insider tranaction occured on November, 6th when President Giuseppe Ciaramella sold 51,110 shares worth more than $1,347,259.60. Insiders at Beam Therapeutics own 4.2% of the company. Learn More about insider trades at Beam Therapeutics.
Information on this page was last updated on 11/6/2024.

Giuseppe Ciaramella Insider Trading History at Beam Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/6/2024	Sell	51,110	$26.36	$1,347,259.60	109,150
10/14/2024	Sell	51,110	$26.27	$1,342,659.70	160,260
4/1/2024	Sell	4,534	$32.12	$145,632.08	169,616
7/24/2023	Sell	1,206	$32.01	$38,604.06	48,250
7/21/2023	Sell	155,324	$32.06	$4,979,687.44	48,250
4/3/2023	Sell	1,918	$30.31	$58,134.58	114,044
12/12/2022	Sell	51,015	$42.70	$2,178,340.50	91,462
3/31/2022	Sell	1,859	$59.11	$109,885.49	115,614
12/21/2021	Sell	25,104	$85.69	$2,151,161.76
6/28/2021	Sell	78,580	$107.35	$8,435,563.00	123,341

Giuseppe Ciaramella Buying and Selling Activity at Beam Therapeutics

Beam Therapeutics Company Overview

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Today's Range

Now: $29.01

$26.74

$29.20

50 Day Range

MA: $25.73

$21.55

$30.35

2 Week Range

Now: $29.01

$20.84

$49.50

Volume

2,744,028 shs

Average Volume

1,233,557 shs

Market Capitalization

$2.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Giuseppe Ciaramella Biography and Net Worth

What is Giuseppe Ciaramella's net worth?

How old is Giuseppe Ciaramella?

What is Giuseppe Ciaramella's salary?

How do I contact Giuseppe Ciaramella?

Has Giuseppe Ciaramella been buying or selling shares of Beam Therapeutics?

Who are Beam Therapeutics' active insiders?

Are insiders buying or selling shares of Beam Therapeutics?